Assaf Debby

Assaf Debby

Auto-generated profile, based on publicly available information

Assaf Debby

Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
EMEttai Markovits
Ettai Markovits
OHOrtal Harush
Ortal Harush
EBErez N. Baruch
Erez N. Baruch
ESEldad D. Shulman
Eldad D. Shulman
ADAssaf Debby
Assaf Debby
GMGal Markel
Gal Markel
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of preimmunotherapy tumor biopsies from patients with melanoma that received PD-1 blockade or adoptive cell therapy with tumor-infiltrating lymphocytes. We identified two melanoma-intrinsic, mutually exclusive gene programs, which were controlled by IFNγ and MYC, and the association with immunotherapy outcome. MYC-overexpressing melanoma cells exhibited lower IFNγ responsiveness, which was linked with JAK2 downregulation. Luciferase activity assays, under the control of JAK2 promoter, demonstrated reduced activity in MYC-overexpressing cells, which was partly reversible upon mutagenesis of a MYC E-box binding site in the JAK2 promoter. Moreover, silencing of MYC or its cofactor MAX with siRNA increased JAK2 expression and IFNγ responsiveness of melanomas, while concomitantly enhancing the effector functions of T cells coincubated with MYC-overexpressing cells. Thus, we propose that MYC plays a pivotal role in immunotherapy resistance through downregulation of JAK2.

21 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NMNaama Margolis
Naama Margolis
HMHanna Moalem
Hanna Moalem
TMTomer Meirson
Tomer Meirson
GGGilli Galore-Haskel
Gilli Galore-Haskel
EMEttai Markovits
Ettai Markovits
GMGal Markel
Gal Markel
The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I–restricted and IFNγ-dependent, as it was abolished by β2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA sequencing (RNA-seq) of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, cocultures of cognate melanoma/T-cell pairs led to IFNγ-dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-seq in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8+ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNγ-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNγ-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNγ, which can drive T-cell infiltration.

5 July 2023
Verified
Other
Open access
EMEttai Markovits
Ettai Markovits
OHOrtal Harush
Ortal Harush
EBErez N. Baruch
Erez N. Baruch
ESEldad D. Shulman
Eldad D. Shulman
ADAssaf Debby
Assaf Debby
GMGal Markel
Gal Markel
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of preimmunotherapy tumor biopsies from patients with melanoma that received PD-1 blockade or adoptive cell therapy with tumor-infiltrating lymphocytes. We identified two melanoma-intrinsic, mutually exclusive gene programs, which were controlled by IFNγ and MYC, and the association with immunotherapy outcome. MYC-overexpressing melanoma cells exhibited lower IFNγ responsiveness, which was linked with JAK2 downregulation. Luciferase activity assays, under the control of JAK2 promoter, demonstrated reduced activity in MYC-overexpressing cells, which was partly reversible upon mutagenesis of a MYC E-box binding site in the JAK2 promoter. Moreover, silencing of MYC or its cofactor MAX with siRNA increased JAK2 expression and IFNγ responsiveness of melanomas, while concomitantly enhancing the effector functions of T cells coincubated with MYC-overexpressing cells. Thus, we propose that MYC plays a pivotal role in immunotherapy resistance through downregulation of JAK2.

5 July 2023
Verified
Other
Open access
EMEttai Markovits
Ettai Markovits
OHOrtal Harush
Ortal Harush
EBErez N. Baruch
Erez N. Baruch
ESEldad D. Shulman
Eldad D. Shulman
ADAssaf Debby
Assaf Debby
GMGal Markel
Gal Markel
Similarity between TIL ACT and PD-1 blockade response mechanism. Related to Figure S1.


5 July 2023
Verified
Other
Open access
EMEttai Markovits
Ettai Markovits
OHOrtal Harush
Ortal Harush
EBErez N. Baruch
Erez N. Baruch
ESEldad D. Shulman
Eldad D. Shulman
ADAssaf Debby
Assaf Debby
GMGal Markel
Gal Markel
Differential gene expression analysis between responders and non-responders to immunotherapy. Related to Figure 1.